| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01968915 | Neoplasms | Drug: LCL161|Drug: Paclitaxel | Novartis Pharmaceuticals|Novartis | Phase 1 | 2013-11-01 | 2016-01-20 |
| NCT01240655 | Solid Tumors | Drug: LCL161|Drug: Paclitaxel | Novartis Pharmaceuticals|Novartis | Phase 1 | 2011-04-01 | 2016-09-01 |
| NCT01934634 | Metastatic Pancreatic Cancer | Drug: LCL161|Drug: Gemcitabine|Drug: nab-Paclitaxel | US Oncology Research|Novartis Pharmaceuticals|Delta Clinical Research, LLC | Phase 1 | 2014-03-01 | 2015-11-07 |
| NCT01955434 | Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma | Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Other: Quality-of-Life Assessment|Drug: Smac Mimetic LCL161 | Mayo Clinic|National Cancer Institute (NCI) | Phase 2 | 2013-11-01 | 2017-03-21 |
| NCT01098838 | Advanced Solid Tumors | Drug: LCL161 | Novartis Pharmaceuticals|Novartis | Phase 1 | 2008-11-01 | 2012-08-02 |
| NCT01617668 | Breast Cancer | Drug: LCL161|Drug: paclitaxel | Novartis Pharmaceuticals|Novartis | Phase 2 | 2012-08-01 | 2016-08-30 |
| NCT02649673 | Small Cell Lung Cancer|Ovarian Cancer | Drug: LCL161|Drug: Topotecan | SCRI Development Innovations, LLC|Novartis Pharmaceuticals | Phase 1|Phase 2 | 2016-03-01 | 2016-09-26 |
| NCT02098161 | Leukemia | Drug: LCL-161|Behavioral: Questionnaires|Other: Phone Calls | M.D. Anderson Cancer Center|Novartis | Phase 2 | 2014-12-01 | 2016-12-05 |
| NCT02890069 | Colorectal Cancer|Non-small Cell Lung Carcinoma (Adenocarcinoma)|Triple Negative Breast Cancer | Biological: PDR001|Drug: LCL161|Drug: Everolimus|Drug: Panobinostat | Novartis Pharmaceuticals|Novartis | Phase 1 | 2016-10-26 | 2017-02-27 |
